The US Bioinformatics Market was valued at $7357.9 Million in 2026 and projected to reach to $13592.8 Million by 2031, representing a compound annual growth rate of 13.1%. The US bioinformatics market is positioned for sustained growth through 2031, driven by technological advancements in genomic analysis, increasing prevalence of chronic diseases, and growing adoption of AI-powered diagnostic tools.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US bioinformatics market is valued at $7,357.9 million in 2026 and is projected to reach $13,592.8 million by 2031, representing a robust 13.1% CAGR over the forecast period.
Increasing adoption of genomic sequencing technologies across US healthcare institutions is driving market expansion, with hospitals and diagnostic centers investing heavily in next-generation sequencing (NGS) platforms and analysis tools.
Rising demand for personalized medicine and precision healthcare in the US is accelerating bioinformatics adoption, as healthcare providers seek to tailor treatments based on individual genetic profiles and biomarkers.
Substantial investments in US healthcare IT infrastructure, including electronic health records (EHR) integration and cloud-based bioinformatics platforms, are creating a mature ecosystem for market growth.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides bioinformatics solutions for genomic data analysis, next-generation sequencing (NGS) workflows, molecular diagnostics, and life science research. Its platforms support sequencing data interpretation, variant analysis, and clinical research applications. | Faster genomic data analysis, improved accuracy in variant interpretation, streamlined NGS workflows, enhanced research productivity, and support for precision medicine development. |
|
|
Offers integrated sequencing and bioinformatics platforms for analyzing large-scale genomic data. Its solutions support applications in oncology, inherited disease research, population genomics, and clinical diagnostics through advanced sequencing data analysis. | Efficient management of complex genomic datasets, improved disease identification, faster biomarker discovery, enhanced clinical decision-making, and acceleration of personalized medicine. |
|
|
Provides bioinformatics software and genomic analysis platforms for sample-to-insight workflows, molecular diagnostics, clinical research, and next-generation sequencing data interpretation. | Simplified data analysis, improved workflow automation, reliable genomic insights, reduced analysis time, and enhanced support for molecular testing and precision healthcare. |
|
|
Develops bioinformatics tools for genomics, transcriptomics, and molecular analysis, supporting applications such as microarray analysis, NGS data interpretation, and biomarker discovery in research and clinical settings. | Improved data visualization and interpretation, increased research efficiency, accurate molecular profiling, faster discovery of biological insights, and optimized laboratory workflows. |
|
|
Provides integrated bioinformatics solutions supporting clinical genomics, companion diagnostics, oncology research, and precision medicine. Its platforms enable genomic data analysis for targeted therapies and biomarker identification. | Enhanced biomarker assessment, faster treatment decisions, improved diagnostic accuracy, optimized clinical workflows, and support for personalized medicine approaches. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | PRECISION MEDICINE (Use Case) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 13.1% from 2026 to 2031 |
| Largest Segment | SOFTWARE (Offering) |
| Market Size Base Year (Billions) | ~USD 18.59 (2026) |
| Revenue Forecast (Billions) | ~USD 34.41 (2031) |
| Segments Covered | Offering, Type, Function, Use Case, Sector, End User |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BECKMAN COULTER | United States | Private Company | Bioinformatics Software (Genomics, Multiomics, Proteomics),Bioinformatics Services (Analysis, Sequencing, Genomic Services), |
| WUXI APPTEC | China | Public Company | Chemical Business,Testing Services,Biological Services, |
| DANAHER CORPORATION | United States | Public Company | Diagnostics,Life Sciences (Excl. Biotechnology),Biotechnology, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing and array-based instruments,Consumables (reagents, flow cells, library preparation, WGS and targeted kits),Services (whole-genome sequencing, genotyping, NIPT, product support, informatics services), |
| QIAGEN N.V. | Netherlands | Public Company | Bioinformatics software (genomics, multiomics, proteomics),Bioinformatics-linked services (analysis, sequencing, interpretation),Non-bioinformatics consumables and instruments, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Agilent CrossLab,Life Sciences and Diagnostics Markets,Applied Markets, |
| REVVITY, INC. | United States | Public Company | Life Sciences,Diagnostics, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Bioinformatics-linked genomics and multiomics services,Non-informatics analytical testing (food, environment, consumer, other), |
| BGI GENOMICS | China | Public Company | Sequencing and Bioinformatics Services,Clinical Testing and Precision Medicine Solutions,Mass Spectrometry and Multi-omics (Proteomics, Metabolomics, Multi-omics Integration), |
| WATERS CORPORATION | United States | Public Company | Waters Segment (LC-MS systems, consumables, and software),Materials Sciences Division (thermal analysis, rheometry, calorimetry), |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | Sequencing instruments (MinION, GridION, PromethION),Consumables and flow cells,Software and bioinformatics services, |
| 10X GENOMICS | United States | Public Company | Single-cell and spatial instruments (Chromium, Chromium X Series, Visium, Xenium Analyzer, CytAssist),Consumables and reagents (microfluidic chips, slides, kits including QuantumScale),Bioinformatics software and analysis services (Cell Ranger, Loupe Browser, Xenium Explorer, associated analysis support), |
| PACBIO | United States | Public Company | Sequencing instruments (Revio, Vega, Sequel, Onso),Consumables (SMRT cells, SMRTbell prep kits, binding and sequencing kits),Software and services (bioinformatics analysis, sequencing services, collaborations), |
| SIEMENS AG | Germany | Public Company | Industrial Businesses (IB) - Siemens Healthineers,Industrial Businesses (IB) - Smart Infrastructure,Industrial Businesses (IB) - Digital Industries, |
| SOPHIA GENETICS | Switzerland | Public Company | SOPHiA DDM Software Platform (Genomics, Multiomics, Proteomics),Services (Analysis Support, Sequencing-Linked Informatics, Implementation), |
Beckman Coulter is a private American company founded in 1935 that employs 11,900 people. The company operates in the life sciences and diagnostics sector.
WuXi AppTec is a public Chinese company founded in 2000 with 35,584 employees. The company provides pharmaceutical and biotechnology research and development services.
Danaher Corporation is a public American company founded in 1969 with 59,000 employees. The company operates across multiple sectors including life sciences, diagnostics, and environmental solutions.
Thermo Fisher Scientific Inc. is a public American company founded in 1956 with 125,000 employees. The company is a leading provider of laboratory equipment, reagents, and services for life sciences research and diagnostics.
Illumina, Inc. is a public American company founded in 1998 with 8,625 employees. The company specializes in DNA sequencing and genetic analysis technologies.
QIAGEN N.V. is a public Dutch company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences products.
Agilent Technologies, Inc. is a public American company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
Revvity, Inc. is a public American company founded in 1937 with 11,000 employees. The company provides analytical instruments and life sciences solutions.
Eurofins Scientific is a public Luxembourg-based company founded in 1987 with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
BGI Genomics is a public Chinese company founded in 1999 with 3,580 employees. The company specializes in genomic sequencing and genetic analysis services.
Waters Corporation is a public American company founded in 1958 with 7,900 employees. The company manufactures analytical instruments and software for laboratory testing and research.
Oxford Nanopore Technologies PLC is a public British company founded in 2005 with 1,316 employees. The company develops nanopore-based DNA and RNA sequencing technologies.
10X Genomics is a public American company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions for research and diagnostics.
PacBio is a public American company founded in 2000 with 485 employees. The company develops long-read DNA sequencing technologies and systems.
Siemens AG is a public German company founded in 1847 with 317,000 employees. The company operates across multiple sectors including industrial automation, energy, healthcare, and infrastructure.
Sophia Genetics is a public Swiss company founded in 2011 with 415 employees. The company provides AI-powered genomic analysis and interpretation software for clinical diagnostics.
The US bioinformatics market is valued at $7,357.9 million in 2026, representing a significant segment of the global healthcare IT landscape.
The US bioinformatics market is forecast to reach $13,592.8 million by 2031, nearly doubling from 2026 levels.
The US bioinformatics market is expected to grow at a compound annual growth rate of 13.1% from 2026 to 2031.
The US market growth is driven by increased genomic sequencing adoption, rising personalized medicine demand, precision oncology applications, and substantial healthcare IT investments.
The US pharmaceutical, biotechnology, and healthcare provider sectors are leading market expansion through adoption of bioinformatics tools for drug discovery, clinical diagnostics, and precision medicine applications.
This research study involved the extensive use of both primary and secondary sources. It analyzed various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
This research study extensively used secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive, commercially focused study of the bioinformatics market, covering technical aspects and market dynamics. It also helped identify key players, market classifications, industry trends, geographic markets, and significant market developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
In the primary research process, various supply-side and demand-side sources were interviewed to gather qualitative and quantitative information for this report. Primary supply-side sources included industry experts such as CEOs, VPs, managing directors, marketing and sales heads/directors, marketing managers, regional/area sales managers, and bioinformatics scientists. Primary demand-side sources included personnel from pharmaceutical and biotechnology companies, hospitals, diagnostic laboratories, and academic and research institutes.
A breakdown of the primary respondents is provided below:

*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The total size of the bioinformatics market was determined after data triangulation using the two approaches outlined below. After each approach was completed, the weighted average of the two approaches was calculated based on the level of assumptions used in each approach.

The size of the bioinformatics market was estimated through segmental extrapolation using the bottom-up approach. The methodology is as follows:
Bioinformatics is the application of computer technology to the management and analysis of biological data. It encompasses the storage, analysis, and dissemination of biological data. Bioinformatics uses computer programs for a variety of applications, including determining gene and protein functions, establishing evolutionary relationships, and predicting the three-dimensional shapes of proteins.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Bioinformatics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report